Based on the Moderna Inc stock forecast from 17 analysts, the average analyst target price for Moderna Inc is USD 52.40 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Moderna Inc’s stock price was USD 25.64. Moderna Inc’s stock price has changed by -9.56% over the past week, -28.00% over the past month and -75.60% over the last year.
No recent analyst target price found for Moderna Inc
No recent average analyst rating found for Moderna Inc
Company Overview Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Read Less
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines c...Read More
Frequently Asked Questions About Moderna Inc (MRNA) Stock
Based on ratings from 17 analysts Moderna Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, 8 sell and 13 hold ratings.
Unfortunately we do not have enough data on MRNA's stock to indicate if its a good dividend stock.
Based on targets from 17 analysts, the average taret price for MRNA is USD 52.40 over the next 12 months. The maximum analyst target price is USD 115 while the minimum anlayst target price is USD 27.
MRNA stock's Price/Earning ratio is 25.72.
Our analysis grades MRNA stock's Price / Earning ratio at F. This means that MRNA stock's Price/Earning ratio is above 75% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MRNA may be a overvalued for its sector.
The last closing price of MRNA's stock was USD 25.64.
The most recent market capitalization for MRNA is USD 13.74B.
Based on targets from 17 analysts, the average taret price for MRNA is projected at USD 52.40 over the next 12 months.
This means that MRNA's stock price may go up by +112.68% over the next 12 months.
We can't find any ETFs which contains Moderna Inc's stock.
As per our most recent records Moderna Inc has 5,800 Employees.
Moderna Inc's registered address is 325 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Moderna Inc's website at https://www.modernatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Moderna Inc (MRNA) Stock
Based on ratings from 17 analysts Moderna Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, 8 sell and 13 hold ratings.
Unfortunately we do not have enough data on MRNA's stock to indicate if its a good dividend stock.
Based on targets from 17 analysts, the average taret price for MRNA is USD 52.40 over the next 12 months. The maximum analyst target price is USD 115 while the minimum anlayst target price is USD 27.
MRNA stock's Price/Earning ratio is 25.72.
Our analysis grades MRNA stock's Price / Earning ratio at F. This means that MRNA stock's Price/Earning ratio is above 75% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MRNA may be a overvalued for its sector.
The last closing price of MRNA's stock was USD 25.64.
The most recent market capitalization for MRNA is USD 13.74B.
Based on targets from 17 analysts, the average taret price for MRNA is projected at USD 52.40 over the next 12 months.
This means that MRNA's stock price may go up by +112.68% over the next 12 months.
We can't find any ETFs which contains Moderna Inc's stock.
As per our most recent records Moderna Inc has 5,800 Employees.
Moderna Inc's registered address is 325 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Moderna Inc's website at https://www.modernatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MRNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
